VT
PTGX icon

Vise Technologies’s Protagonist Therapeutics PTGX Stock Holding History

Vise Technologies’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,996
Closed -$262K – 1927
2026
Q1 		$262K Hold
2,996
– – 0.01% 1219
2025
Q4 		$262K Buy
+2,996
New +$245K 0.01% 1227

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vise Technologies's PTGX Position: Q2 2026 in Review

Vise Technologies sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 2,996 shares — an estimated $262K sold.

Vise Technologies first reported a position in PTGX in Q4 2025 and held it in 2 quarters. The position peaked at $262K in Q1 2026. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Vise Technologies reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vise Technologies sold 2,996 Protagonist Therapeutics shares in Q2 2026, an estimated $262K.
  • Vise Technologies first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 2 quarters.
  • Vise Technologies's Protagonist Therapeutics position peaked at $262K in Q1 2026.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.